Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly will spend $3 billion expanding a recently acquired manufacturing facility in Wisconsin to provide capacity for injectable products, including its fast-growing obesity and diabetes drugs.

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.

We continued to make progress on our manufacturing build-out, and U.S. supply across all doses of tirzepatide was available throughout Q4," said David A. Ricks, Lilly chair and CEO. "The rest of ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in ...

WEST LAFAYETTE, Ind. — Purdue University, in collaboration with Eli Lilly and Company and Merck & Co. Inc., announced Friday (Jan. 17) the launch of the Young Institute Pharmaceutical Manufacturing ...

Long-term growth is supported by new product launches, expanded manufacturing capacity, and a robust pipeline, positioning Eli Lilly for sustained success. On January 14th, Eli Lilly (NYSE ...

which undercut the branded versions of the drugs while Lilly, Novo Nordisk and others made substantial investments into their manufacturing capacities. More recently, FDA announced the resolution ...

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...